Moderna and Merck's personalized mRNA cancer vaccine cut melanoma recurrence risk by 42%
The therapy, given with Keytruda, cut the risk of distant metastasis or death by 38%, and overall survival data remain immature
We haven't written up this one. Quartz has the full story — the link below goes straight to it.